TY  - JOUR
AU  - Stintzing, Sebastian
AU  - Klein-Scory, Susanne
AU  - Fischer von Weikersthal, Ludwig
AU  - Fuchs, Martin
AU  - Kaiser, Florian
AU  - Heinrich, Kathrin
AU  - Modest, Dominik Paul
AU  - Hofheinz, Ralf-Dieter
AU  - Decker, Thomas
AU  - Gerger, Armin
AU  - Angermeier, Stefan
AU  - Rumpold, Holger
AU  - Dickhut, Andreas
AU  - Öhler, Leopold
AU  - Gruenberger, Birgit
AU  - Niedersuess-Beke, Dora
AU  - Sandmann, Matthias
AU  - Winder, Thomas
AU  - Trojan, Joerg
AU  - Prager, Gerald
AU  - Held, Swantje
AU  - Kumbrink, Jörg
AU  - Schmiegel, Wolff
AU  - Baraniskin, Alexander
AU  - Heinemann, Volker
TI  - Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
JO  - Journal of clinical oncology
VL  - 43
IS  - 12
SN  - 0732-183X
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2025-00290
SP  - 1463-1473
PY  - 2025
N1  - 2025 Apr 20;43(12):1463-1473
AB  - The FIRE-4 study randomly assigned patients with first-line RAS wild-type (RASwt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) or to FOLFIRI plus cetuximab followed by a switch maintenance treatment using FU plus bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) RAS and BRAF testing compared with tissue-based analyses.LBs were taken at baseline and during treatment and were analyzed for RAS and BRAFV600E mutations using the in vitro diagnostics-certified ONCOBEAM RAS procedure (Sysmex Inostics) and digital-droplet polymerase chain reaction technology.Six hundred seventy-two RASwt patients were randomly assigned. LBs of 540 patients were evaluable at baseline. Of those, 70 (13
LB  - PUB:(DE-HGF)16
C6  - pmid:39903881
DO  - DOI:10.1200/JCO.24.01174
UR  - https://inrepo02.dkfz.de/record/298573
ER  -